Picture supply: Getty Pictures
The market has lately moved on from all issues synthetic intelligence (AI), focusing as an alternative on international commerce and tariffs. However within the background, the AI revolution continues apace and is disrupting some companies. One is Chegg (NYSE: CHGG), which was buying and selling for $113 in 2021 however is now priced as a penny share at $0.75.
That’s a stunning four-year decline of 99%!
An instance of disruption
Chegg is an training know-how firm that provides providers like textbook leases, homework assist, and research assets. Its clients are primarily school and highschool college students.
Nonetheless, as we all know, generative AI bots like ChatGPT now — considerably controversially — provide free assist with homework and essays, undermining Chegg’s worth proposition. Principally, college students appear to be considering: ‘why pay for Chegg when AI provides you free solutions?’
In 2023, administration stated: “Since March we noticed a major spike in scholar curiosity in ChatGPT. We now imagine it’s having an affect on our new buyer development price.”
Chegg was proper. In two years, its subscribers have gone from 5.1m to three.2m, with income falling from $188m to $121m in that point. Worryingly, its money place has fallen from $281m in Q1 2023 to simply $44m on the finish of March (and it’s now loss-making).
To attempt to enhance issues, the corporate is drastically slicing prices and exploring being acquired. Maybe that may salvage some worth (the market cap is now simply $79m).
It’s additionally licensing its question-and-answer pairs to language mannequin corporations, although that seems to be a double-edged sword to me. Sure, it’s producing income by leveraging proprietary training knowledge, however giving AI corporations its content material may cannibalise the core subscription enterprise.
Right this moment (12 Might), Chegg’s administration wrote: “We imagine the developments impacting our enterprise will worsen earlier than they get higher.”
These “developments” are, in fact, primarily declining subscribers resulting from competitors from generative AI.
AI isn’t a single occasion
Many individuals have likened AI to the web, but it surely does seem totally different to me.
Whereas revolutionary, the web was a one-time platform shift. However AI isn’t a single watershed second. Fairly, it’s a self-improving power, continuously studying and evolving, maybe exponentially.
Consequently, I anticipate much more disruption — and potential alternatives — within the years forward.
This inventory appears in no hazard from AI
In fact, there can be some companies that AI received’t damage. It ought to even make them extra environment friendly and worthwhile. Many of those could be discovered within the FTSE 100, together with miners, international banks, and oil giants.
One UK inventory that is likely to be value contemplating is AstraZeneca. It’s down 16% since March as buyers fear concerning the Trump administration’s drive to decrease drug costs within the US. It is a danger value mentioning, because the US is AstraZeneca’s largest market.
Nonetheless, when it comes to AI, the know-how may really turbocharge the corporate’s drug discovery course of. Not solely that, however AstraZeneca has the wherewithal to actually put money into its AI capabilities, in contrast to most smaller upstarts.
To me, the agency appears extra more likely to profit from AI than be threatened by it. With the inventory buying and selling at an inexpensive 15 instances ahead earnings, I feel it’s value a glance.
